Navigation Links
Data Showing that ReGen's Colostrinin Supports Healthy Cognitive,Function Presented at the 2007 International Congress on Natural,Medicine in Australia

London, UK, June 11, 2007-ReGen is pleased to announce that a review of scientific and clinical information on Colostrinin, its nutraceutical product which the Company believes has the potential to support healthy cognitive function, was presented today at the 2007 International Congress on Natural Medicine in Surfers Paradise, Queensland, Australia by Dr Marian Kruzel, ReGen's Chief Scientific Officer.

The conference, which is being attended by key opinion leaders and practitioners of natural medicine from around the world, is being sponsored by Metagenics Inc. of California via its Australian affiliate company Health World Ltd.

Metagenics have licensed the rights to Colostrinin(TM) for the North American market and intend to introduce it in the USA as a nutritional supplement during the last quarter of 2007.

Dr. Kruzel presented both pre-clinical and human clinical data showing that Colostrinin(TM):
reduces the production of intracellular reactive oxygen species (ROS). These increase with old age and are associated with tissue and metabolic Damage prevents the aggregation of beta-amyloid and its consequent neurotoxicity. This is a protein associated with Alzheimer's disease increases the lifespan of mice prone to premature ageing by around 30% when given in the drinking water is well-tolerated and without adverse effect when given to animals at doses up to 100 times that recommended for humans daily for prolonged periods had beneficial effects on the cognitive and functional performance of around 150 human subjects in clinical trials with mild to moderate Alzheimer's disease.

Commenting after his presentation Dr. Kruzel said, 'The audience here is extraordinary, it includes physicians, health care professionals and many other disciplines concerned about wellbeing in rapidly aging societies. It is a great pleasure to have the opportunity to present our cutting edge scientific research that validates the efficacy of nutrace
'"/>




Page: 1 2

Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
3. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
4. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
5. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
6. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
7. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
8. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
9. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
10. LigoCyte Pharmaceuticals Presents Data Showing Heterosubtypic Protection Against Influenza Challenge With Virus-Like Particle Immunization
11. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke

Post Your Comments:
(Date:11/24/2009)...-FirstCall/--Orexigen®Therapeutics,Inc.(Nasda...atmentofobesity,todayannouncedthatonNovember18,200...ctorsgrantedaninducementstockoptiontopurchase200,0...yappointedHeadoftheGlobalContraveProgram. ,, Th...theextentpermittedbylawandhasanexercisepricepersha...
(Date:11/24/2009)...ewswire-FirstCall/--NeurogesX,Inc.(Nasdaq: NGSX ),...mercializingnovelpainmanagementtherapies,todayanno...ors,effectiveNovember19,2009.Mr.Orwinisa20-yearsal...yandhasbeeninstrumentalinthelaunchofseveralimporta...iorVicePresident,BioOncologyBusinessUnitatGenentec...
(Date:11/23/2009)...--TwooftheChicagoarea,sleadingBoardCertifiedDiagno...stimaging,couplingthelatesttechnologyindigitalmamm...bilitytohavethefullrangeofdigitalimagingcompleted,...theoffice.Drs.AhmedFaragandJoanWerberaredelivering...onthwaitforanappointmentcommonlyfoundinChicago,fro...
Breaking Medicine Technology:Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 2Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 3NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director 2NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director 3Parents In Kansas Can Now Test Their Children For Lead Exposure Using Saliva 47727 1Parents In Kansas Can Now Test Their Children For Lead Exposure Using Saliva 47727 2Parents In Kansas Can Now Test Their Children For Lead Exposure Using Saliva 47727 3Parents In Kansas Can Now Test Their Children For Lead Exposure Using Saliva 47727 4Next generation software system for flood warning and risk analysis to be developed 8704 1Next generation software system for flood warning and risk analysis to be developed 8704 2Cell Therapeutics Amends and Restates Its Modified Dutch Auction Tender Offer to a Fixed Price Tender Offer for Any and All of Its 24118 9 Million Ou 12433 1Cell Therapeutics Amends and Restates Its Modified Dutch Auction Tender Offer to a Fixed Price Tender Offer for Any and All of Its 24118 9 Million Ou 12433 2Cell Therapeutics Amends and Restates Its Modified Dutch Auction Tender Offer to a Fixed Price Tender Offer for Any and All of Its 24118 9 Million Ou 12433 3Cell Therapeutics Amends and Restates Its Modified Dutch Auction Tender Offer to a Fixed Price Tender Offer for Any and All of Its 24118 9 Million Ou 12433 4
...nc. (CTI) announces data presented at AACR-NCI-EOR...RANCISCO, Oct. 26 Cell Therapeutics,Inc. (CTI) (N...M), a,wholly-owned subsidiary of CTI, announced ne...ates during the 19th annual AACR-NCI-EORTC Symposi... identifying specific,tumor types with a higher li...
...ch Provides Tolerable and Effective Symptom Contro...SHPGY, TSX: SHQ), the global specialty biopharmace...h study of DAYTRANA(TM) (methylphenidate,transderm...sorder (ADHD),patch, demonstrated that DAYTRANA pr...ontrol improvement in children aged 6 to 12 years....
Other Medicine Technology:Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 2Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 4Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 5Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 2Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 3Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 4Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 5
(Date:11/24/2009)...Newswire/--Whiletheholidayseasonoftenbringsfamilie...nbedifficultforthosegrievingthedeathofalovedone.Fo...ilies.Theholidayseasoncanbringadditionalchallenges...e,ACenterforGrievingChildren,AdolescentsandTheirFa...ntohavingavarietyofprintandonlineresourcesavailabl...
(Date:11/24/2009)...PRNewswire-USNewswire/--Dr.NelsonEscobar,aphysicia...ientoftheJamesBradyAward.Theawardwaspresentedtohim...eirannualconferenceonOctober30,2009. ,, Accordi...ecognitionofhisexpertiseinaddressingthecomplexneed...entandexceptionalcareofhispatientsandtheirfamilies...
(Date:11/24/2009)...Newswire/--TheUnionLaborLifeInsuranceCompany("Unio...®),()thenation,slargestvisionbenefitsandservi...stounions,uniontrustfunds,unionemployersandtheirme...gservicesincludingcomprehensiveeyeexams,broadselec...antqualityeyecareis,"statedBruceSmith,NationalSale...
(Date:11/24/2009)...wswire-FirstCall/--CenteneCorporation(NYSE: CNC )t...asselectedCenteneasoneoftwoCoordinatedCareOrganiza...sNetwork(MississippiCAN),acoordinatedcareprogramfo...withtheDivisiontoexecuteacontractinwhichthecompany...liaHealthPlan(Magnolia). ,, BasedinJackson,Miss...
(Date:11/24/2009)...ing hazard, are too loud, or contain dangerous che...ews) -- As the holiday shopping season begins, par...ll being sold in stores across the United States. ...uble in Toyland report, released Tuesday by the U...e report focuses on toys that pose a choking hazar...
Breaking Medicine News(10 mins):Health News:Highmark Caring Place Resources Help Children and Families Who Are Grieving During the Holidays 2Health News:Marianjoy Medical Group Physician Receives James Brady Award 2Health News:Union Labor Life & VSP Vision Care Align to Offer Vision Insurance Products 2Health News:Centene Corporation Receives Notification of Intent to Contract From the State of Mississippi 2Health News:Dangerous Toys Still on Store Shelves, Report Finds 2Health News:Dangerous Toys Still on Store Shelves, Report Finds 3
...21, 2008 A recent study shows that pre-operative a...cal therapists allow for early diagnosis and succe...cted by the National Naval Medical Center (NNMC) a...e journal, Cancer (April 25, 2008). The authors d...
..., discomfort may be driving factor, study suggests...eople with asthma may be at increased risk for sui... suicidal thoughts without suicide attempts, accor...der, from the U.S. National Comorbidity Survey Rep...
... REVERSE MENTAL ACUITY DEFICITS IN SMOKERS WHO,ARE...view to Address FAA,Ruling on Smoking Cessation Pr... Federal Aviation,Administration (FAA) that it has...this news does not include NRT, which,is deemed sa...
...subgroup of participants in the Womens Health Init...sts that healthy, postmenopausal women whose blood... increased, short-term risk for heart attack when ...) cholesterol to high-density lipoprotein (HDL, or...
...er cells from embryonic stem cells, find clues to ...y 23 (HealthDay News) -- Human liver cells have be... model, hopefully opening the door to help scienti...s that were presented this week at Digestive Disea...
...ompanies establishing online personal health recor...king robotic surgery routine, it makes sense to ha...ursing staff, care managers and other healthcare w...stem. , Akio Koyama of Yamagata University, Japan...
Other Medicine News:Health News:New study shows positive role physical therapists play in lymphedema diagnois and treatment 2Health News:Asthma Associated With Suicidal Thoughts, Attempts 2Health News:MultiVu Video Feed: FREE NICOTINE REPLACEMENT THERAPY (NRT) TO BE OFFERED TO REGISTERED PILOTS INTERESTED IN QUITTING RELIEF IN LIGHT OF RECENT FAA RULINGS 2Health News:Blood cholesterol levels predict risk of heart disease due to hormone therapy 2Health News:New Hope for Liver Diseases 2Health News:New Hope for Liver Diseases 3Health News:Remote-control health 2
...ceMate is the industry's most powerful, comprehens...vailable. In fact, OfficeMate is the most widely u...t of every three computerized eyecare businesses u... practice management needs including patient demog...
Winx Pro Practice Management Software for Eyecare Professionals
E-Z Frame Platinum
VitalWorks Intuition PM Ophthalmology
Medicine Products: